PSK2 PSOBEST. EFFECTIVENESS AND SAFETY OF LONG-TERM SYSTEMIC PSORIASIS-THERAPY: PATIENT REGISTRY OF HEALTH SERVICES IN GERMANY  by Rustenbach, SJ et al.
CLUSION: Secondary prophylactic treatment with tacrolimus
0.1% ointment is more effective, leads to cost savings and higher
QoL in comparison to standard tacrolimus 0.1% ointment use,
especially in patients with severe AD.
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PSOBEST. EFFECTIVENESS AND SAFETY OF LONG-TERM
SYSTEMIC PSORIASIS-THERAPY: PATIENT REGISTRY OF
HEALTH SERVICES IN GERMANY
Rustenbach SJ, Schäfer IA, Radke M,Augustin M
University Clinics of Hamburg, Hamburg, Germany
OBJECTIVES: Treatment of severe Psoriasis (Pso) and Psoriasis-
Arthritis (PsA) is largely conﬁned to conventional systemic-
therapy in Germany, though authorisation of biologics greatly
enhanced the therapy-spectrum. While short- and middle-term
efﬁcacy of systemic-therapy has been shown in many clinical
studies (and is incorporated in international guidelines), knowl-
edge about long-term outcome, optimal treatment and real world
effectiveness is still missing. PsoBEST, the German registry of
systemic treatments in moderate to severe Pso and PsA starts in
2007 and will document the long-term course of patients ﬁrst
entrained to a biologic or conventional systemic. Objectives are
the observation and analysis of following outcomes of systemic
antipsoriatrics authorisized: Effectiveness of real world, long-
term, combined/alternating treatments and under comorbidity
conditions. Patient-deﬁned beneﬁts, maintenance dosages, pre-
diction of response and safety. METHODS: A nationwide sample
of initially 250 (long-term approx. 500) dermatologic practices/
hospital ambulances with expertise in systemic and biologic
treatment will enrol patients consecutively. Patients will remain
in the registry for 5 years, regardless of subsequential therapy.
Study phase 1 will cover n = 3500 patients in 7 cohorts, for
which recruitment will be continued up to n = 500. Documenta-
tion will comprise patient/treatment characteristics, clinical
parameters, patient-deﬁned beneﬁt (PBI), quality of life and
adverse events. Standardized questionnaires are provided to
patients and practitioners 12 times at the dermatologic centres
and 9 times postal at interim intervals (patients residence).
Requirements of Volume 9a (EMEA) and of relevant interna-
tional guidelines on outcomes research in observational studies
are incorporated. PsoBest is aligned to planned EU-registries
(GB, N, S, E and F), relevant endpoints are comparable. Scientiﬁc
quality is assured by an interdisciplinary advisory board, AWMF,
EMEA and BfArM involvement/consultation and certiﬁcation by
DIN ISO 9001:2000. Descriptive reports will be generated regu-
larly, hypotheses will be tested e.g. by MAN(C) OVA, multiple/
logistic/ survival regression and multilevel modelling.
Comparisons between cohorts will be achieved by propensity
score matching.
PSK3
W
IT
HD
RA
W
N
PSK4
COST COMPARISON BETWEENTWO ANTI-TUMOR
NECROSIS FACTOR (ANTI-TNF)THERAPIES IN PATIENTS
WITH PSORIASIS USING AVERAGE SALES PRICE
Tang B, Rahman MI,Thompson HC, Hilliard R, Naim A, Dabbous O
Centocor, Inc, Horsham, PA, USA
OBJECTIVES: To compare annual costs of anti-TNF therapies in
patients with psoriasis (PsO). METHODS: A decision-model was
created using TreeAge software, with clinical trial data and
average sales price (ASP) +6% (2Q 2007) for drug costs. Two
treatment strategies were compared: etanercept ﬁrst then switch-
ing to inﬂiximab and inﬂiximab ﬁrst then switching to etaner-
cept. The model assumed patients who failed to achieve Psoriasis
Area and Severity Index (PASI)-50 would switch to the other
biologic after 24 weeks. The efﬁcacy rates after switching were
assumed to be the same as the ﬁrst-line treatment. A sensitivity
analysis reducing the efﬁcacy rates after switching by 10%-30%
was conducted. The cost of adverse events was not included in
the model. Infusion fees ($237.92/infusion–2Q 2007) were
included for inﬂiximab. RESULTS: With inﬂiximab, 90% of
patients achieved PASI-50 at week-24 and continued receiving
inﬂiximab. Patients (10%) who failed to achieve PASI-50
were switched to etanercept. With etanercept, 77% of patients
achieved PASI-50 at week-24 and continued etanercept
treatment. Patients (23%) who failed to achieve PASI-50 were
switched to inﬂiximab. The etanercept-ﬁrst strategy costs
$22,113 annually and results in an overall efﬁcacy rate of 78.5%
and a cost-efﬁcacy (CE) of $28,171. The inﬂiximab-ﬁrst strategy
costs $23,544 annually and results in an 89.4% efﬁcacy rate and
a CE of $26,351. Compared with etanercept, the inﬂiximab-ﬁrst
strategy costs $1820 less per PASI-50 response. The incremental
CE ratio per PASI-50 was $13,190. The sensitivity analysis indi-
cated that the results are robust and in the same direction as the
original assumption. CONCLUSION: This decision model dem-
onstrates that an inﬂiximab-ﬁrst strategy is more cost-effective
than an etanercept-ﬁrst strategy in the treatment of psoriasis.
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